At the recent IMPAKT Breast Cancer Conference, 2 – 4th May, Brussels, ecancer´s Peter Goodwin talks to Ana Vivancos about her pioneering research in cancer genomics and work contributing to improved phase I clinical studies and best therapies for patients.
Related Posts
ESMO 2019 Annual Congress to be held in Barcelona
Source: European Society for Medical Oncology (ESMO) ESMO, the leading European professional organisation for medical oncology, has announced that the…
13 Jun 2017
Novel drug reduces risk of metastatic prostate cancer progression by 81%
Presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 03, Chicago IL, USA, the Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) have participated in an international phase III study published in the New England Journal of Medicine. Findings show that the administration of the drug enzalutamide prior to chemotherapy in metastatic prostate cancer patients reduces disease progression of by 81% — consequently postponing initiation of treatment with the latter, and leading to increased survival and improved quality of life for patients.
02 Jun 2014
VHIO preclinical study predicts therapeutic avenue for pancreatic cancer
Pancreatic cancer is one of the most aggressive forms of cancer as well as one of the least responsive to…
15 Apr 2015
The European Research Council (ERC) awards prestigious €1.7 M ‘Consolidator Grant’ to VHIO in recognition of scientific excellence
Laura Soucek has been awarded an ERC Consolidator Grant for research into novel Myc inhibitor agents
21 Jan 2014
Vote Joan Seoane as recipient of the Vanguardia de la Ciencia prize
The Spanish periodical La Vanguardia has opened voting online for the recipient of this year´s Vanguardia de la Ciencia annual…
16 Feb 2016
VHIO researchers discover that a subgroup of breast tumors constitutes a unique type of cancer by itself
Based on the genomic analysis of 6 tumor types, VHIO´s Translational Genomics Group has established that breast tumors of the…
19 Dec 2013
WIN Consortium and Pfizer Collaborate to Advance Personalized Cancer Care
The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium, of which the Vall d´Hebron Institute of Oncology (VHIO) is…
17 Dec 2012
Launched: VHIO´s Schools and Science Education Programme
VHIO opens its doors to bright young minds to learn about cancer research and discover science as a career path…
18 Oct 2017
Josep Tabernero listed among the Highly Cited Researchers 2016: representing some of the world´s most influential scientific minds
In the recently announced Highly Cited Researcher listing 2016 by Clarivate Analytics – formerly the IP & Science business of…
21 Nov 2016
An independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Service top of the leaderboard for second consecutive year
Barcelona, 18 November 2015.-According to a second independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria…
18 Nov 2015
2016 independent nationwide evaluation ranks Vall d´Hebron´s Medical Oncology Department top of the leaderboard for third consecutive year
According to a third independent, annual benchmark evaluation of the Spanish healthcare sector, Monitor de Reputación Sanitaria (MRS), issued by…
14 Dec 2016
Fero Community´s annual fundraising gala dinner and award ceremony: a record-breaking celebration
Celebrated last week and returning to the stunning Oval Room of Catalonia´s National Museum of Art (MNAC), Fero´s community joined…
15 May 2017
VHIO study exploits premature aging of cells as a treatment strategy for HER2+ breast tumors
Barcelona, May 22, 2015.– Research led by the Vall d’Hebron Institute of Oncology´s Growth Factors Group headed by Joaquín Arribas,…
25 May 2015
Improved tracking & targeting of the HER/EGFR family: ESMO Symposium on Signalling Pathways in Cancer, 04 – 05 March 2016, Sitges, Barcelona
Under the expert Co-Chairship of Josep Tabernero, Director of the Vall d´Hebron Institute of Oncology (VHIO), and Clare Isacke, The…
08 Jan 2016
Calling Young Scientists: deadline extended to 04 August to apply for EurocanPlatform´s Translational Cancer Research Course, 20 – 24 October 2014, Portugal
Aimed at exploring all aspects of the translational research continuum, from early detection through treatment to survivorship, this special 5-day…
10 Jul 2014
